These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3898494)

  • 1. Failure of cyclosporine to prevent in vivo T cell priming in man. Studies in allogeneic spleen transplantation.
    Gonwa TA; Goeken NE; Schulak JA; Nghiem DD; Corry RJ
    Transplantation; 1985 Sep; 40(3):299-304. PubMed ID: 3898494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The in vivo immunosuppressive action of suppressor cells from alloantigen-cyclosporine-treated mice and the capacity of spleen cells to release interleukins and gamma-interferon.
    Yoshimura N; Matsui S; Hamashima T; Kita M; Oka T
    Transplantation; 1988 Jan; 45(1):157-62. PubMed ID: 2962348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human in vivo cytotoxic T lymphocyte generation by cyclosporine following organ transplantation.
    Keown PA; Essery-Rice G; Hellstrom A; Sinclair NR; Stiller CR
    Transplantation; 1985 Jul; 40(1):45-9. PubMed ID: 3892796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Host resistance to cyclosporine induced syngeneic graft-versus-host disease. Requirement for two distinct lymphocyte subsets.
    Fischer AC; Laulis MK; Horwitz L; Beschorner WE; Hess A
    J Immunol; 1989 Aug; 143(3):827-32. PubMed ID: 2526175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclosporine-induced tolerance in experimental organ transplantation. Evidence of diminished donor-specific cytotoxicity relative to donor-specific proliferative response.
    Norin AJ; Kamholz SL; Pinsker KL; Emeson EE; Veith FJ
    J Immunol; 1987 Jul; 139(2):332-7. PubMed ID: 2955037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of acute GVHD and prolongation of rat pancreas allograft survival with DST cyclosporine, and spleen transplantation.
    Wakely E; Oberholser JH; Corry RJ
    Transplantation; 1990 Feb; 49(2):241-5. PubMed ID: 2305452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific tolerance and immunocompetence in haploidentical, but not in completely allogeneic, canine chimeras treated with methotrexate and cyclosporine.
    Deeg HJ; Severns E; Raff RF; Sale GE; Storb R
    Transplantation; 1987 Nov; 44(5):621-32. PubMed ID: 2961110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that cyclosporine does not inhibit allograft rejection by IL-2-treated sensitized splenocytes.
    Kemeny MM; Stephens DA
    Transplantation; 1987 Apr; 43(4):560-3. PubMed ID: 3554645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of exogenous interleukin-10 on cardiac allograft survival: inhibition of rejection by recipient pretreatment reflects impaired host accessory cell function.
    Li W; Fu F; Lu L; Narula SK; Fung JJ; Thomson AW; Qian S
    Transplantation; 1999 Nov; 68(9):1402-9. PubMed ID: 10573082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunopharmacodynamic evaluation of cyclosporine-treated renal allograft recipients.
    Rogers AJ; Yoshimura N; Kerman RH; Kahan BD
    Transplantation; 1984 Dec; 38(6):657-64. PubMed ID: 6239413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of action of cyclosporine A in vivo. II. T cell priming in vivo to alloantigen can be mediated by an IL-2-independent cyclosporine A-resistant pathway.
    Pereira GM; Miller JF; Shevach EM
    J Immunol; 1990 Mar; 144(6):2109-16. PubMed ID: 1968924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking of interleukin-2 production, but not the tissue destruction induced by cytotoxic T cells, by cyclosporine.
    Noble RL; Steinmuller D
    Transplantation; 1989 Feb; 47(2):322-6. PubMed ID: 2784016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine: a new immunosuppressive agent for organ transplantation.
    Cohen DJ; Loertscher R; Rubin MF; Tilney NL; Carpenter CB; Strom TB
    Ann Intern Med; 1984 Nov; 101(5):667-82. PubMed ID: 6385799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of permanent mixed chimerism and skin allograft tolerance across fully MHC-mismatched barriers by the additional myelosuppressive treatments in mice primed with allogeneic spleen cells followed by cyclophosphamide.
    Tomita Y; Yoshikawa M; Zhang QW; Shimizu I; Okano S; Iwai T; Yasui H; Nomoto K
    J Immunol; 2000 Jul; 165(1):34-41. PubMed ID: 10861032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft.
    Herzog WR; Zanker B; Irschick E; Huber C; Franz HE; Wagner H; Kabelitz D
    Transplantation; 1987 Mar; 43(3):384-9. PubMed ID: 3547795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reepithelialized orthotopic tracheal allografts expand memory cytotoxic T lymphocytes but show no evidence of chronic rejection.
    Cleven HA; Genden EM; Moran TM
    Transplantation; 2005 Apr; 79(8):861-8. PubMed ID: 15849536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inhibitory effects of pravastatin on natural killer cell activity in vivo and on cytotoxic T lymphocyte activity in vitro.
    Katznelson S; Wang XM; Chia D; Ozawa M; Zhong HP; Hirata M; Terasaki PI; Kobashigawa JA
    J Heart Lung Transplant; 1998 Apr; 17(4):335-40. PubMed ID: 9588577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of cyclosporine on in situ cellular and humoral immune responses during allograft rejection.
    Orosz CG; Sirinek LP; Zinn NE; Ferguson RM
    Transplant Proc; 1987 Feb; 19(1 Pt 2):1175-7. PubMed ID: 3274303
    [No Abstract]   [Full Text] [Related]  

  • 19. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival.
    Lu L; Li W; Fu F; Chambers FG; Qian S; Fung JJ; Thomson AW
    Transplantation; 1997 Dec; 64(12):1808-15. PubMed ID: 9422424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thioredoxin priming prolongs lung allograft survival by promoting immune tolerance.
    Hu H; Zhu X; Joshi S; Lu L; Xia CQ; Patel JM
    PLoS One; 2015; 10(5):e0124705. PubMed ID: 25933390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.